...
首页> 外文期刊>The regulatory affairs journal: Pharma >European Court Judgment Changes the Rules for Dominant Companies-Bill Batchelor highlights the far-reaching implications of the AstraZeneca judgment.
【24h】

European Court Judgment Changes the Rules for Dominant Companies-Bill Batchelor highlights the far-reaching implications of the AstraZeneca judgment.

机译:欧洲法院判决改变了主要公司的规则-Bill Batchelor强调了阿斯利康判决的深远影响。

获取原文
获取原文并翻译 | 示例
           

摘要

On 1 July 2010, the European Union General Court handed down its judgment in the long-running saga of AstraZeneca's proton pump inhibitor anti-ulcer product, Losec (omeprazole). Although dealing with events that happened almost two decades ago, the case - barring appeal - is set to cast a long shadow over the activities of patent and regulatory professionals.
机译:2010年7月1日,欧盟总法院就长期存在的阿斯利康质子泵抑制剂抗溃疡药Losec(奥美拉唑)的传奇做出了判决。尽管处理了将近20年前发生的事件,但此案-禁止上诉-必将给专利和监管专业人员的活动蒙上阴影。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号